## **Erratum:** Atezolizumab-Induced Hypothyroidism in a Patient With Preexisting Triiodothyronine (T3) Thyrotoxicosis Due to Graves' Disease: A Case Report and Literature Review

Article published 11/19/2021 Article corrected 11/22/2021

Samson O. Oyibo<sup>1</sup>, Mohamed O. Mahgoub<sup>2</sup>

1. Diabetes and Endocrinology, Peterborough City Hospital, Peterborough, GBR 2. Oncology, Peterborough City Hospital, Peterborough, GBR

Corresponding author: Samson O. Oyibo, samoyibo@yahoo.co.uk

Corresponding author: Samson O. Oyibo

1. Diabetes and Endocrinology, Peterborough City Hospital, Peterborough, GBR 2. Oncology, Peterborough City Hospital, Peterborough, GBR

## How to cite this erratum

Oyibo S O, Mahgoub M O (November 22, 2021) Correction: Atezolizumab-Induced Hypothyroidism in a Patient With Pre-existing Triiodothyronine (T3) Thyrotoxicosis Due to Graves' Disease: A Case Report and Literature Review. Cureus 13(11): c53. doi:10.7759/cureus.c53

## **Correction Notice**

Shortly after publication, the submitting author realized that two statistical values in Table 1 had been entered incorrectly during the article submission process. As a result, we have corrected Table 1 to include the proper values as these were incorrectly transposed in the original version submitted to and published in Cureus:

Free thyroxine (pmol/L): 36.3

Free triiodothyronine (pmol/L): 19.3